| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | MS-275 | CTRPv2 | pan-cancer | AAC | -0.073 | 0.03 |
| mRNA | Axitinib | GDSC1000 | pan-cancer | AAC | -0.08 | 0.03 |
| mRNA | Bortezomib | CTRPv2 | pan-cancer | AAC | -0.078 | 0.03 |
| mRNA | Cytarabine | GDSC1000 | pan-cancer | AAC | -0.079 | 0.03 |
| mRNA | TAE684 | CTRPv2 | pan-cancer | AAC | -0.078 | 0.03 |
| mRNA | GNF-2 | GDSC1000 | pan-cancer | AAC | -0.12 | 0.03 |
| mRNA | BRD-K29086754 | CTRPv2 | pan-cancer | AAC | -0.16 | 0.03 |
| mRNA | HG-6-64-1 | GDSC1000 | pan-cancer | AAC | -0.075 | 0.03 |
| mRNA | selumetinib:BRD-A02303741 (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.077 | 0.03 |
| mRNA | BMS-345541 | CTRPv2 | pan-cancer | AAC | -0.08 | 0.03 |